Skip to main content

Table 6 Genotypes of 8 SNPs of FGFR gene and their associations with adverse events

From: Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Target Gene Polymorphisms/Genotype Toxicity(grade 3–4)
N = 102(48%)
No toxicity (grade1–2)
N = 109(52%)
OR (95%CI) P P HWE
FGFR1 rs2288696      0.035
  C/C 85(83.3%) 88(80.7%) Reference   
  C/T 14(13.7%) 19(17.4%) 0.76(0.36—1.62) 0.480  
  T/T 3(2.9%) 2(1.8%) 1.55(0.25—9.53) 0.634  
  Dominat model 17(16.7%) 21(19.3%) 0.84(0.41—1.70) 0.624  
  Recessive model 99(97.1%) 107(98.2%) 0.62(0.10—3.77) 0.601  
  Alleles      
  C 184(90.2%) 195(89.4%) Reference   
  T 20(9.8%) 23(10.6%) 0.92(0.49—1.73) 0.800  
FGFR2 rs2981582      0.138
  C/C 52(51.0%) 47(43.1%) Reference   
  C/T 37(36.3%) 47(43.1%) 0.71(0.40—1.28) 0.253  
  T/T 13(12.7%) 15(13.8%) 0.78(0.34—1.82) 0.569  
  Dominat model 50(49.0%) 62(56.9%) 0.73(0.42—1.25) 0.253  
  Recessive model 89(87.3%) 94(86.2%) 1.09(0.49—2.43) 0.828  
  Alleles      
  C 141(69.1%) 141(64.7%) Reference   
  T 63(30.9%) 77(35.3%) 0.82(0.55—1.30) 0.333  
  rs1219648      0.726
  A/A 34(33.3%) 33(30.3%) Reference   
  A/G 49(48.0%) 57(52.3%) 0.83(0.45—1.54) 0.562  
  G/G 19(18.6%) 19(17.4%) 0.97(0.44—2.15) 0.941  
  Dominat model 68(66.7%) 76(69.7%) 0.87(0.49—1.55) 0.634  
  Recessive model 83(81.4%) 90(82.6%) 0.92(0.46—1.86) 0.821  
  Alleles      
  A 117(57.4%) 123(56.4%) Reference   
  G 87(42.6%) 95(43.6%) 0.96(0.66—1.42) 0.847  
  rs2420946      0.172
  T/T 13(12.7%) 22(20.2%) Reference   
  C/T 39(38.2%) 51(46.8%) 1.29(0.58—2.89) 0.529  
  C/C 50(49.0%) 36(33.0%) 2.35(1.05—5.28) 0.038*  
  Dominat model 89(87.3%) 87(79.8%) 1.73(0.82—3.65) 0.150  
  Recessive model 52(51.0%) 73(67.0%) 0.51(0.29—0.90) 0.019*  
  Alleles      
  T 65(31.9%) 95(43.6%) Reference   
  C 139(68.1%) 123(56.4%) 1.65(1.11—2.46) 0.013*  
  rs2981579      0.196
  T/T 29(28.4%) 25(22.9%) Reference   
  C/T 38(37.3%) 58(53.2%) 0.57(0.29—1.11) 0.096  
  C/C 35(34.3%) 26(23.9%) 1.16(0.56—2.43) 0.692  
  Dominant model 73(71.6%) 84(77.1%) 0.75(0.40—1.39) 0.361  
  Recessive model 67(65.7%) 83(76.1%) 0.60(0.33—1.09) 0.095  
  Alleles      
  T 96(47.1%) 108(49.5%) Reference   
  C 108(52.9%) 110(50.5%) 1.11(0.75—1.62) 0.610  
  rs2981578      0.909
  G/G 30(29.4%) 70(64.2%) Reference   
  A/G 61(59.8%) 29(26.6) 4.91(2.65—9.08) < 0.0001*  
  A/A 11(10.8%) 10(9.1%) 2.57(0.99—6.69) 0.054  
  Dominant model 72(70.6%) 39(35.8%) 2.57(0.99–6.69) < 0.0001*  
  Recessive model 91(89.2%) 99(90.8%) 0.84(0.34–2.06) 0.697  
  Alleles      
  G 121(59.3%) 169(82.8%) Reference   
  A 83(40.7%) 49(24.0%) 2.37(1.55—3.61) < 0.0001*  
FGFR3 rs743682      0.682
  G/G 85(83.3%) 92(84.4%) Reference   
  A/G 15(14.7%) 17(15.6%) 0.96(0.45—2.03) 0.955  
  A/A 2(2.0%) 0 0.00 0.999  
  Dominant model 17(16.7%) 17(15.6%) 1.08(0.52—2.26) 0.833  
  Recessive model 100(98.0%) 109(100.0%) 0.00 0.999  
  Alleles      
  G 185(90.7%) 201(92.2%) Reference   
  A 19(9.3%) 17(7.8%) 1.21(0.61—2.41) 0.578  
FGFR4 rs1966265      0.998
  G/G 22(21.6%) 19(17.4%) Reference   
  A/G 46(45.1%) 58(53.2%) 0.69(0.33—1.42) 0.307  
  A/A 34(33.3%) 32(29.4%) 0.92(0.42—2.00) 0.829  
  Dominant model 80(78.4%) 90(82.6%) 0.77(0.39—1.52) 0.449  
  Recessive model 68(66.7%) 77(70.6%) 0.83(0.46—1.49) 0.534  
  Alleles      
  G 90(44.1%) 96(44. %) Reference   
  A 114(55.9%) 122(56.0%) 1.00(0.68—1.46) 0.987  
  1. OR odds ratio, 95% CI 95% confidence interval, * A P value < 0.05 was considered ststistically significant